Loading organizations...
§ Private Profile · Raleigh, NC, USA
Tryton Medical is a technology company.
Tryton Medical develops and commercializes advanced medical devices for treating complex coronary artery disease, specifically focusing on bifurcation lesions. Its core offering is the Tryton Side Branch Stent, the only FDA-approved bifurcated stent, which utilizes proprietary Tri-ZONE technology to simplify treatment and achieve predictable outcomes in challenging arterial anatomies. This specialized stent system is designed to provide optimal coverage and support for both the main vessel and the side branch.
The company was co-founded in 2003 by Aaron V. Kaplan, M.D., and H. Richard Davis, with an initial insight to address the significant challenges associated with traditional stenting approaches for coronary artery bifurcations. Dr. Kaplan, an Associate Professor of Medicine at Dartmouth Medical School, brought clinical expertise to the development, while Mr. Davis contributed to establishing the operational and manufacturing aspects of the company. Their combined vision aimed to provide a dedicated solution for this unmet medical need.
Tryton Medical’s products serve interventional cardiologists and their patients worldwide who require treatment for coronary artery bifurcation lesions. The company’s long-term vision centers on improving patient care and procedural success rates for these complex interventions by continually innovating stent technology. It strives to establish its bifurcated stent as the standard of care, ultimately enhancing clinical outcomes and simplifying treatment paradigms in cardiovascular medicine.
Tryton Medical has raised $108.0M across 5 funding rounds.
Tryton Medical has raised $108.0M in total across 5 funding rounds.
Tryton Medical is a medical technology company specializing in cardiovascular devices, primarily developing the Tryton Side Branch Stent for treating coronary bifurcation lesions—points where arteries branch, often challenging in interventional cardiology.[1][2][4][7] The stent serves cardiologists and healthcare providers managing patients with complex coronary artery disease, solving the problem of incomplete coverage and suboptimal outcomes in side branch treatment by providing a dedicated, deployable solution alongside conventional main vessel stents.[1][2][4][5][7] Founded in 2003 and based in Durham, North Carolina, the company has raised $87M total, reaching Series G stage, with its FDA-approved device marking U.S. commercial launch around 2021 after global use in over 12,000 patients.[1][2]
Tryton Medical was founded in 2003 by Aaron V. Kaplan, M.D., a professor of medicine at the Geisel School of Medicine/Dartmouth-Hitchcock Medical Center, who identified the need for specialized stents to definitively treat bifurcation lesions in coronary arteries.[2] The idea emerged from gaps in existing cardiology interventions, where standard stents inadequately addressed side branches, prompting development of proprietary technology.[1][2][4] Early traction built through European, Middle East, and Africa commercialization, culminating in U.S. FDA approval as the only dedicated bifurcated stent and the first U.S. commercial case at New York-Presbyterian Hospital/Columbia University Medical Center.[2][7]
Tryton rides the trend of advancing interventional cardiology for complex coronary disease, where bifurcations account for 15-20% of lesions but historically yield higher complication rates with generic stents.[1][2] Timing aligns with rising percutaneous coronary interventions amid aging populations and diabetes-driven atherosclerosis, bolstered by FDA approval enabling U.S. market access post-global validation.[1][2][7] Market forces like demand for precise, outcome-predictable devices favor Tryton, influencing the ecosystem by setting a standard for bifurcation-specific tech and potentially expanding to peripherals or imaging integrations.[1][3][5]
Tryton is poised for U.S. market penetration with its独占 FDA-approved bifurcation stent, potentially accelerating revenue after $4M raised eight years ago.[1] Trends like AI-guided imaging and bioresorbable materials could enhance its Tri-ZONE platform, while partnerships with majors like Boston Scientific (evident in ecosystem ties) may drive scale.[1][2] Its influence may evolve from niche innovator to bifurcation treatment leader, simplifying procedures and improving patient outcomes in a $7B+ coronary stent market—reinforcing its role as the go-to for these high-risk anatomies.[1][7]
Tryton Medical has raised $108.0M across 5 funding rounds. Most recently, it raised $20.0M Other Equity in September 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 8, 2014 | $20M Venture Round | — | 3X5 Special Opportunity Fund, Alejandro Sanchez, RiverVest Venture Partners | Announced |
| Sep 1, 2014 | $20M Series U | — | Rivervest, 3X5 Special Opportunity Fund, Canepa U.S., RiverVest Venture Partners | Announced |
| Jan 8, 2013 | $24M Venture Round | Rick Anderson | 3X5 Special Opportunity Fund, RiverVest Venture Partners, Spray Venture Partners | Announced |
| Jan 1, 2013 | $24M Series U | PTV Sciences | Rivervest, 3X5 Special Opportunity Fund, RiverVest Venture Partners, Spray Venture Partners | Announced |
| Sep 1, 2010 | $20M Series D | Arnerich Massena | Rivervest, PTV Sciences, RiverVest Venture Partners, Spray Venture Partners | Announced |
Tryton Medical has raised $108.0M in total across 5 funding rounds.
Tryton Medical's investors include 3x5 Special Opportunity Fund, Alejandro Sanchez, RiverVest Venture Partners, RiverVest, Canepa U.S., Rick Anderson, Spray Venture Partners, PTV Sciences, Arnerich Massena.